Evidence map›Paper›PMID 27721583›Full record

ArticleAnnals of neurosciences2016

A Novel Way of Amelioration of Amyloid Beta Induced Toxicity in

Kopal Saharia, Ranjeet Kumar, Kuldeep Gupta, Shrilekha Mishra, Jamuna R Subramaniam

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of neurosciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Kopal SahariaDepartment of Biological Sciences and Bioengineering, Indian Institute of Technology, Kanpur, India; Department of Bioscience and Biotechnology, Banasthali University, Banasthali Vidyapith, India.
Ranjeet KumarDepartment of Biological Sciences and Bioengineering, Indian Institute of Technology, Kanpur, India.
Kuldeep GuptaDepartment of Biological Sciences and Bioengineering, Indian Institute of Technology, Kanpur, India.
Shrilekha MishraDepartment of Bioscience and Biotechnology, Banasthali University, Banasthali Vidyapith, India.
Jamuna R SubramaniamDepartment of Biological Sciences and Bioengineering, Indian Institute of Technology, Kanpur, India; Center for Preclinical and Translational Medicine Research, Central Research Facility, Sri Ramachandra University, Chennai, India.
Indian Institute of Technology Kanpur · INBanasthali University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWith an incidence of 1 in 85 persons above the age of 60 years succumbing to the disease, Alzheimer's disease (AD), has been predicted to create havoc globally. In spite of enormous efforts and exhaustive research, no cure is in sight. Hence, it is critical to unravel the mechanism of AD development/protection and identification of a cure soon. PURPOSE: This study is aimed at investigating the mechanism of reserpine action, which alleviates the toxicity of amyloid beta (Aβ) (AD-causing peptide) in

methodsDetermination of alleviation of Aβ toxicity with reserpine manifested as reduction in progressive paralysis, in the background of GFP reporter driven by the promoter of the FMRFamide neuropeptide, FLP-11 (AD; P

resultsThe most significant protection against Aβ toxicity was obtained in the background of P

conclusionA unique way to alleviate Aβ toxicity is reserpine treatment in combination with P

Indexed as

AcetylcholineAlzheimer diseaseAmyloid betaFLP-11Neuropeptide

Identifiers

PMID27721583
PMCPMC5043337
OpenAlexW2530883861

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.